<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html lang="en">

<head>
  <title>A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia - Full Text View - ClinicalTrials.gov</title>
    <meta name="robots" content="noindex,nofollow"/>
    <meta http-equiv="Content-Type" content="text/html;charset=UTF-8"/>
    <link href="/ct2/show/NCT00386334" rel="canonical"/>
    <link href="/ct2/html/images/frame/icon.ico" rel="SHORTCUT ICON"/>
  <link href="/ct2/html/images/frame/ct.css" type="text/css" rel="stylesheet"/>
  <script type="text/javascript" src="/ct2/html/images/frame/ct.js" language="JavaScript">
  </script>
</head>

<body style="min-width:720px; margin-left:0px; margin-right:0px; margin-top:0px" onload="doLoadActions();">

<!-- small_banner -->
<div class="skip"><a href="#MainContent">Skip to Main Content</a></div>

<table class="layout_table banner_color" cellspacing="0" cellpadding="0" border="0" width="100%">
  <tr>
    <td align="left" style="padding:6px" nowrap>
      <a title="Show Home Page" href="/ct2/home">
        <img alt="ClinicalTrials.gov" src="/ct2/html/images/frame/small_title.gif" border="0"/>
      </a>
    </td>

    <td class="header3" align="right" style="padding:3px 12px 3px 3px;" nowrap>
            <a style="margin-left:1em;" title="Show Home Page" href="/ct2/home">Home</a>
            <a style="margin-left:1em;" title="Show Search Page" href="/ct2/search">Search</a>
            <a style="margin-left:1em;" title="Show Study Topics Page" href="/ct2/search/browse">Study Topics</a>
            <a style="margin-left:1em;" title="Show Glossary Page" href="/ct2/info/glossary">Glossary</a>
            <br/>
      <form method="get" action="/ct2/results" style="margin-top:0.5ex; margin-bottom:0px;">
        <input class="body3" type="text" name="term" alt="Quick Search" title="Quick Search" value="" size="30" maxlength="250"/>
        <input class="header3" type="submit" alt="Search" value="Search"/>
        
      </form>
    </td>
  </tr>
</table>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<a name="MainContent" id="skipnav"></a>


<!-- above_tabs -->
<div class="show_back_color">
<br/>


</div>








<!-- tabs -->
<div class="show_back_color header3">
<table class="layout_table" cellpadding="0" cellspacing="0" border="0">
  <tr valign="bottom">
            <td valign="bottom"><img style="width:20px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="fore_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_fore.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_fore.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5ex 1.0em" nowrap >
            <span class="header2">Full Text View</span>
          </td>
          <td align="right"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img width="1" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td/>
          <td align="right"><img width="2" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Tabular View Page" href="/ct2/show/record/NCT00386334?term=eszopiclone" >Tabular View</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Study Results Page" href="/ct2/show/results/NCT00386334?term=eszopiclone" >Study Results</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td valign="bottom"><img style="width:50px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Related Studies Page" href="/ct2/show/related/NCT00386334?term=eszopiclone" >Related Studies</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom" width="100%"><img style="width:100%; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
  </tr>
</table>
</div>

<!-- Title section -->
<div class="indent3" align="center">

    <div class="header1" style="margin-top:3ex;">A Long-Term Safety and Efficacy Study of <span class="hit_org">Eszopiclone</span> in Elderly With Primary Chronic Insomnia</div>
  
      <div class="header2" style="margin-top:2ex; color:  red  ">
    This study has been completed.
  </div>
      
  
  <div style="margin-top:2ex">
    First Received: October 9, 2006 &nbsp;
          Last Updated: November 2, 2010 &nbsp;
      <a href="/ct2/archive/NCT00386334"
        title="Historical versions of study NCT00386334 on ClinicalTrials.gov Archive Site"
        onclick="openNewWindow('/ct2/archive/NCT00386334'); return false;">History of Changes</a>
      </div>

  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="50%" style="margin:2ex 0;">

        <tr>
      <th align="right" nowrap class="header3 pale_banner_color"> Sponsor: </th>
      <td align="left" nowrap class="body2"> Sunovion </td>
    </tr>
    
    
        <tr>
      <th align="right" nowrap class="header3 pale_banner_color">Information provided by: </th>
      <td align="left" nowrap class="body2">Sunovion</td>
    </tr>
    
    <tr>
      <th align="right" nowrap class="header3 pale_banner_color">ClinicalTrials.gov Identifier: </th>
      <td align="left" nowrap class="body2">NCT00386334</td>
    </tr>

  </table>

</div>
  
<!-- purpose_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Purpose</span>

<div class="indent2" style="margin-top:2ex">

  <div class="body3"><p style="margin-top:1ex; margin-bottom:1ex;">To evaluate the long-term safety and efficacy of <span class="hit_org">eszopiclone</span> administered for 12 weeks in elderly subjects with primary chronic insomnia.Administration of <span class="hit_org">eszopiclone</span> 2 mg daily at bedtime for 12 weeks in elderly subjects with a diagnosis of primary chronic insomnia will be safe and well tolerated, improve subjective sleep measures, improve measures of Quality of Life and next day insomnia symptoms, and have no significant withdrawal central nervous system adverse events or rebound insomnia.</p></div><br/>

    <!-- condition, intervention, phase summary table -->
  <div align="center">
  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="80%">
    <tr align="left">
            <th class="header3 pale_banner_color">
        <a href="/ct2/help/conditions_desc" title="Help on Conditions field" onclick="openPopupWindow('/ct2/help/conditions_desc',false); return false;">Condition</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">Intervention</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/phase_desc" title="Help on Phase field" onclick="openPopupWindow('/ct2/help/phase_desc',false); return false;">Phase</a>
      </th>
          </tr>
    <tr align="left" valign="top">
            <td class="body3" nowrap>
                Insomnia<br/>
              </td>
                  <td class="body3" nowrap>
                Drug: <span class="hit_org">Eszopiclone</span><br/>
                Drug: Placebo<br/>
              </td>
                  <td class="body3" nowrap>
                Phase IV<br/>
              </td>
          </tr>
  </table>
  </div>
  <br/>
  
  
  <table class="layout_table" style="margin-bottom:2ex;" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Study Type:</td>
      <td style="padding-left:1em">
        Interventional
              </td>
    </tr>
            <tr valign="top">
      <td nowrap>Study Design:</td>
      <td style="padding-left:1em">Allocation:&#160;Randomized<br/>Control:&#160;Placebo&#160;Control<br/>Endpoint&#160;Classification:&#160;Safety/Efficacy&#160;Study<br/>Intervention&#160;Model:&#160;Parallel&#160;Assignment<br/>Masking:&#160;Double&#160;Blind&#160;(Subject,&#160;Investigator,&#160;Outcomes&#160;Assessor)<br/>Primary&#160;Purpose:&#160;Treatment</td>
    </tr>
            <tr valign="top">
      <td nowrap style="padding-top:2ex">Official Title:</td>
      <td style="padding-left:1em; padding-top:2ex">A Long-Term Safety and Efficacy Study of <span class="hit_org">Eszopiclone</span> in Elderly Subjects With Primary Chronic Insomnia</td>
    </tr>
      </table>

    <!-- NLM links -->
  <br/>
  <div class="header3">Resource links provided by NLM:</div>
  <br/>
  <div class="indent3">

  
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a href="http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp" title="Drug Information Portal" onclick="openNewWindow('http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp'); return false">Drug Information</a> available for:
            <a style="padding-left:0.5em;" href="/ct2/bye/jQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789P1grd-3eBcaZdN8." title="Eszopiclone at ChemIDplus site" onclick="openNewWindow('/ct2/bye/jQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789P1grd-3eBcaZdN8.'); return false">Eszopiclone</a>
          </div>
  
  <a href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>


  
  <br/>
  
  </div>
  
    <!-- more details -->
  <br/>
  <div class="header3">Further study details as provided by Sunovion:</div>
  <br/>
  <div class="indent3">

        <!-- primary outcomes -->
    <div class="body3">Primary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-Reported Total Sleep Time (TST) Averaged Over the 12 Week Double Blind Study Period. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose)-12 weeks&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The difference between the total sleep time at baseline and the average total sleep time over the double blind period(average of post-dose values from weeks 3,6,9,12) reported by the participant.  The change is calculated as the average over the double blind period minus the baseline value.</div><br/>
            </ul>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="body3">Secondary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Total Sleep Time at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0, 3, 6, 9, 12, 14, 16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The difference between the total sleep time at baseline and at different time points in the double-blind period (weeks 3,6,9,12), the single-blind follow-up (week 14) and the non-drug treatment follow-up (week 16).  The change is calculated as the time point value minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-reported Total Sleep Time in Minutes at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0, 3, 6, 9, 12, 14, 16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The mean total minutes asleep each night at different time points:  baseline(week 0), double-blind phase(weeks 3,6,9,12), the single-blind follow-up(week 14),the non-drug treatment follow-up(week 16), and the double-blind average(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Sleep Latency (SL) Averaged Over the 12 Week Double Blind Period. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - Week12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Sleep latency answers how long it takes to fall asleep.  The difference between the sleep latency at baseline and the average sleep latency over the double blind period(average of post-dose values from weeks 3,6,9,12) reported by the participant.  The change is calculated as the average over the double blind period minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Sleep Latency at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Sleep latency answers the question:  How long did it take you to fall asleep last night?  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-reported Sleep Latency Reported at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Sleep latency answers the question: How long did it take you to fall asleep last night?  Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the entire double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) Averaged Over the 12 Week Double-blind Study Period. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) -week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Wake time after sleep onset (WASO) is the time spent awake from sleep onset to final awakening.  The difference between WASO at baseline and the average WASO over the double blind period(average of post-dose values from weeks 3,6,9,12).  The change is calculated as the average over the double blind period minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Wake time after sleep onset is the time spent awake from sleep onset to final awakening. The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-reported Wake Time After Sleep Onset (WASO) at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the entire double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Number of Awakenings Averaged Over the 12 Week Double Blind Study Period. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - Week12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The number of awakenings is the number of times a subject wakes up between the initial onset of sleep and the final awakening. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in the Number of Subject-reported Awakenings at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The number of awakenings refers to the number of times a subject wakes up between the initial onset of sleep and the final awakening.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Number of Awakenings (Subject-reported) at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Number of awakenings is number of times a subject wakes up between initial onset of sleep and final awakening.  Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Quality of Sleep Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - Week12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Quality of sleep was rated by participants on a scale of 0-10, with higher scores representing better quality sleep.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Quality of Sleep at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Sleep quality was rated by subjects on a scale from 0-10, with higher scores representing better quality sleep.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Ratings of Subject-reported Quality of Sleep at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Quality of sleep was rated by participants on a scale of 0-10, with higher scores representing better quality sleep.  Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-Reported Depth of Sleep for the Average Reported During the Double-blind Period. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Depth of Sleep at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-reported Depth of Sleep at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Depth of sleep was reported by study participants using a scale from 0-10, with higher scores representing better sleep.  Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change in Subject-reported Daytime Alertness Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Daytime Alertness at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-reported Daytime Alertness at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Daytime alertness was rated by study participants on a scale of 0-10, with higher scores representing better alertness.  Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-Reported Ability to Function Averaged Over the 12 Week Double Blind Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Ability to Function at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-reported Ability to Function at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Ability to function was rated by study participants on a scale of 0-10, with higher scores representing better ability to function.  Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16) &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Ability to Concentrate Averaged Over the 12 Week Double Blind Study Period. [&nbsp;Time&nbsp;Frame:&nbsp;Baseliine (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Ability to Concentrate at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-reported Ability to Concentrate at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Ability to concentrate was rated by study participants on a scale of 0-10, with higher scores representing better concentration.  Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16) &amp; average for the double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Physical Well-Being Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-reported Physical Well-being at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-reported Physical Well-Being at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Physical well-being was rated by study participants on a scale of 0-10, with higher scores representing better well-being.  Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-Reported Counts of Number of Naps Per Week Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose)- week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the number of naps per week for subjects who napped during the baseline period.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline In Subject-Reported Counts of Number of Naps Per Week at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the number of naps per week for subjects who napped during the baseline period.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-Reported Number of Naps Each Week at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The mean number of naps per week for subjects who napped during the baseline period.  Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change in Subject-Reported Total Nap Time Per Week Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the total time (minutes) spent napping per week for subjects who napped during the baseline period. The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-Reported Total Nap Time Per Week at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the total time (minutes) spent napping per week for subjects who napped during the baseline period.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-Reported Total Nap Time at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The total time (minutes) spent napping per week for subjects who napped during the baseline period.  Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-Reported Total Nap Time Per Week as a Percent of Total Asleep Time Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the total time spent napping per week stated as a percentage of the total time asleep for subjects who napped during the baseline period.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Subject-Reported Total Nap Time Stated as a Percentage of the Total Asleep Time at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the total time spent napping per week stated as a percentage of the total time asleep for subjects who napped during the baseline period.  The change is calculated as value during double-blind phase(weeks 3,6,9,12), or the single-blind follow-up(week 14), or the non-drug treatment follow-up(week 16) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Subject-Reported Total Nap Time Per Week Stated as a Percentage of the Total Asleep Time at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Total time spent napping per week stated as a percentage of total time asleep for subjects who napped during baseline period.  Mean values reported: baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week14), non-drug treatment follow-up(week 16), &amp; average for double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Total Sleep Time Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Participants who wore an actigraph wrist monitor, which monitors rest and activity cycles are included;  the resultant data had total sleep time calculated by a Central Reader.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Total Sleep Time Measured by Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in total sleep time for the subset population who wore an actigraph wrist monitor.  The actigraph monitors rest and activity cycles;  the resultant data had sleep parameters calculated by a Central Reader.  The change is calculated as time point value minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Total Sleep Time Measured by Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Total sleep time for subset who wore actigraph wrist monitor which monitors rest and activity cycles, sleep parameters calculated by Central Reader.  Mean values reported:baseline(week0), double-blind(weeks1,4,7,12), single-blind follow-up(week13), non-drug follow-up(week15) &amp; average for double-blind(average of weeks1,4,7,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Sleep Latency Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Sleep latency is the time it takes to fall asleep.  Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Sleep Latency Measured Using Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Sleep latency is a measurement of the time it takes to fall asleep.  Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Sleep Latency Values Measured Using Actigraphy at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Sleep latency:measurement of time to fall asleep.  Values are for subset who wore an actigraph wrist monitor which monitors rest and activity cycles;  sleep parameters calculated by Central Reader.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Wake Time After Sleep Onset (WASO) Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Change is calculated as average over double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Wake time after sleep onset is the time spent awake from sleep onset to final awakening. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Values for Wake Time After Sleep Onset Measured Using Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;weeks 0,1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Wake time after sleep onset is time spent awake from sleep onset to final awakening. Mean values reported: baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15) &amp; average for double-blind phase(average of weeks 1,4,7,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Number of Awakenings Using Actigraphy Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Change is calculated as average over double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in the Number of Awakenings Measured Using Actigraphy at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Number of Awakenings Measured Using Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Number of awakenings refers to the number of times a subject awakens between first sleep onset to final awakening. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Number of Naps Per Week Measured Using Actigraphy Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the number of naps per week for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in the Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the number of naps per week for subjects who napped during the baseline period. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Number of Naps Per Week Measured Using Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Week 0,1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The number of naps per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline Total Nap Time Per Week Measured by Actigraphy Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the total nap time per week for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the total nap time per week for subjects who napped during the baseline period. Participants who wore an actigraph wrist monitor to record rest and activity cycles are included; a Central Reader calculated sleep parameters. The change is calculated as time point value minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Total Nap Time Per Week Measured by Actigraphy at Various Study Time Points. [&nbsp;Time&nbsp;Frame:&nbsp;Week 0,1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The total nap time per week for subjects who napped during the baseline period. Mean values are reported at baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15), and the average for the double-blind phase(average of weeks 1,4,7,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time Measured by Actigraphy and Averaged Over the 12 Week Double Blind Study Period. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the total time spent napping per week as a percent of the total time asleep for subjects who napped during the baseline period. Change is calculated as the average over the double blind period (average of post-dose values from weeks 1,4,7,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Total Nap Time Per Week as a Percentage of Total Asleep Time as Measured by Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in total time spent napping per week as a percent of total time asleep for subjects who napped during the baseline period. Change is calculated as time point value minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Total Nap Time Per Week as a Percentage of Total Asleep Time Measured Using Actigraphy at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Week 0,1,4,7,12,13,15&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The total time spent napping per week as a percent of the total time asleep for subjects who napped during the baseline period. Mean values reported: baseline(week 0), double-blind phase(weeks 1,4,7,12), single-blind follow-up(week 13), non-drug treatment follow-up(week 15) &amp; average for double-blind phase(average of weeks 1,4,7,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Insomnia Severity Index Total Score Averaged Over the 12 Week Double Blind Study Period [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Day 1 (post first dose) - week 12&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the Insomnia Severity Index Total Score which ranges from 0-28.  Lower scores represent better sleep.  The change is calculated as the average over the double blind period (average of post-dose values from weeks 3,6,9,12) minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Insomnia Severity Index Total Score at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Change from baseline in the Insomnia Severity Index Total Score which ranges from 0-28.  Lower scores represent better sleep.  The change is calculated as time point value minus the baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Insomnia Severity Index Total Scores at Various Study Time Points [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,3,6,9,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">The Insomnia Severity Index Total Score ranges from 0-28.  Lower scores represent better sleep.  Mean values are reported at baseline(week 0), double-blind phase(weeks 3,6,9,12), single-blind follow-up(week 14), non-drug treatment follow-up(week 16), and the average for the double-blind phase(average of weeks 3,6,9,12 values).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Physical Component Summary of the Short Form-36 Scale [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 6, 12, 16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Physical component summary of Short Form-36 Scale measures subject's perception of their physical health, where the normal mean for general US population is 50.Scores above/below 50 represent better than/worse than the general US population.  Higher scores represent better outcomes.  Change is calculated as time point value minus baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Physical Component Summary of the Short Form-36 Scale Scores. [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,6,12,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">This scale measures subject's perception of their physical health, where the normal mean for general US population is 50.Scores above/below 50 represent better/worse than general US population. Change calculated as time point value minus baseline value: baseline(week0), double-blind (weeks 6,12)and non-drug treatment follow-up(week16).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in Mental Component Summary of the Short Form-36 Scale Scores [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 6,12,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Mental component summary of Short Form-36 Scale measures subject's perception of their physical health, where the normal mean for general US population is 50. Scores above/below 50 represent better than/worse than the general US population. Higher scores represent better outcomes. Change is calculated as time point value minus baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Mental Component Summary of the Short Form-36 Scale Scores [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,6,12,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">This scale measures subject's perception of their physical health, where normal mean for general US population is 50. Scores above/below 50 represent better/worse than general US population. Change calculated: time point value minus baseline value.  Mean values: baseline(week0), double-blind phase(weeks 6,12)&amp; non-drug treatment follow-up(week 16).</div><br/>
            <li style="margin-top:0.7ex;">Mean Change From Baseline in the Sheehan Disability Scale Total Score. [&nbsp;Time&nbsp;Frame:&nbsp;Baseline (week 0), Weeks 6,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Sheehan Disability Scale Total Score (range 0-30)measures subject's level of disability &amp; includes: work/school, social life, family life/home responsibilities, days lost &amp;days underproductive; higher scores represent higher degree of disability/impairment.  Change is calculated as time point value minus baseline value.</div><br/>
            <li style="margin-top:0.7ex;">Mean Sheehan Disability Total Scores [&nbsp;Time&nbsp;Frame:&nbsp;Weeks 0,6,12,14,16&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<div class="indent2" style="margin-top:1ex;">Sheehan Disability Scale Total Score (range 0-30) measures subject's level of disability; includes work/school, social life, family life/home responsibilities, days lost, days underproductive; higher scores represent higher degree of disability/impairment.  Mean values reported: baseline, double-blind(weeks 6,12)&amp; follow-up(weeks 14,16).</div><br/>
            </ul>
    </div>
    <br/>
    
    
    <table class="layout_table" style="margin-bottom:3ex;" cellpadding="0" cellspacing="0" border="0">
            <tr valign="top">
        <td nowrap> Enrollment:</td>
        <td style="padding-left:1em">388</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Start Date:</td>
        <td style="padding-left:1em">October 2006</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Completion Date:</td>
        <td style="padding-left:1em">February 2008</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Primary Completion Date:</td>
        <td style="padding-left:1em">February 2008 (Final data collection date for primary outcome measure)</td>
      </tr>
          </table>

        <!-- arms and groups table -->
    <div align="center">
    <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="100%">
      <tr align="left">
        <th class="header3 pale_banner_color">
          <a href="/ct2/help/arm_group_desc" title="Help on Arm Group field" onclick="openPopupWindow('/ct2/help/arm_group_desc',false); return false;">
             Arms           </a>
        </th>
                <th class="header3 pale_banner_color">
          <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">
            Assigned Interventions
          </a>
        </th>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          Placebo: Placebo Comparator
<div class="indent2" style="margin-top:0.5ex">Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Drug: Placebo</div>
        </td>
                <td class="body3">
                      Drug: Placebo
<div class="indent2" style="margin-top:0.5ex">Tablet one per day in the evening.</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          <span class="hit_org">Eszopiclone</span>: Experimental
<div class="indent2" style="margin-top:0.5ex">Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of <span class="hit_org">eszopiclone</span> in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.</div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Drug: <span class="hit_org">Eszopiclone</span></li>
<li>Drug: Placebo</li>
</ul>
</div>
        </td>
                <td class="body3">
                      Drug: <span class="hit_org">Eszopiclone</span>
<div class="indent2" style="margin-top:0.5ex">2 mg tablet once per day in the evening</div>
<div class="indent2" style="margin-top:0.5ex">Other Name: <span class="hit_syn">Lunesta</span></div>
                      Drug: Placebo
<div class="indent2" style="margin-top:0.5ex">Tablet one per day in the evening.</div>
                  </td>
              </tr>
          </table>
    </div>
    <br/>
    
    
    <a name="desc" id="desc"></a>

    
    
        <!-- detailed description -->
    <span class="header3">Detailed Description:</span>
    <div class="body3"><p style="margin-top:1ex; margin-bottom:1ex;">A double-blind, randomized, placebo controlled, parallel group study of eszopiclone in elderly subjects with primary chronic insomnia.  The study will involve up to 9 visits and subject participation will be approximately 18 weeks. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.</p></div>
        
  </div>
  
</div>
</div>
  
<!-- eligibility_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
  <img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Eligibility</span><br/>

  <br/>
  <div class="indent2">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0">
            <tr>
        <td nowrap>Ages Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">65 Years to 85 Years</td>
      </tr>
                  <tr>
        <td nowrap>Genders Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">Both</td>
      </tr>
                  <tr>
        <td nowrap>Accepts Healthy Volunteers: &nbsp; </td>
        <td style="padding-left:1em">No</td>
      </tr>
                </table>

    
        <div class="header3" style="margin-top:2ex">Criteria</div>
    <div class="indent2"><p style="margin-top:0ex; margin-bottom:1ex;">Inclusion Criteria:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Male and female subjects with primary chronic insomnia. Subject is otherwise in good general health, based on screening physical examination and medical history.</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Subject has recent history of known clinically significant abnormal laboratory findings.</li>
</ul></div>
    
  </div>

</div>

  
<!-- location_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Contacts and Locations</span><br/>

<div class="indent2" style="margin-top:2ex">

    Please refer to this study by its ClinicalTrials.gov identifier: NCT00386334<br/>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
  <a name="locn" id="locn"></a>

    <img style="float:left" border="0" src="/ct2/html/images/frame/plus.gif" alt=""/>&nbsp;
  <a class="header3" title="Show 81 study locations" href="/ct2/show/study/NCT00386334?term=eszopiclone&amp;show_locs=Y#locn">Show 81 Study Locations</a><br/>

  
  <!-- sponsors -->
    <div class="header3" style="margin-top:2ex">Sponsors and Collaborators</div>
    <div class="indent2" style="margin-top:1ex">Sunovion</div>
    
  <!-- investigators -->
    <div class="header3" style="margin-top:2ex">Investigators</div>
  <table class="layout_table indent2" cellspacing="0" cellpadding="0" border="0">
        <tr>
      <td style="padding:1ex 1em 0px 0px" nowrap>Study Chair:</td>
      <td style="padding:1ex 1em 0px 0px" nowrap>Medical Director, CNS</td>
            <td style="padding:1ex 1em 0px 0px" nowrap>Sunovion</td>
                </tr>
      </table>
  

</div>
</div>

<!-- more_info_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; More Information</span>

<div class="indent2">
  <br/>


    Additional Information:
    <div class="indent2" style="margin-top:2ex">
        <a href="/ct2/bye/KQoPWw4lZX-i-iSxvi7xzw-PkXNgZdD9kBN9LijaLdNHFihjZB7yZi1VmdoHu61gWBDxlihLvscze64LWd-3uB162B7yZi1PRi7xzw-Pk/5CoHu61gWBD3VB1Pe67xWnjzuw-PSi7gWQ79uwS3Nd-nJH1gz" title="Lunesta Patient Instructions for Use" onclick="openNewWindow('/ct2/bye/KQoPWw4lZX-i-iSxvi7xzw-PkXNgZdD9kBN9LijaLdNHFihjZB7yZi1VmdoHu61gWBDxlihLvscze64LWd-3uB162B7yZi1PRi7xzw-Pk/5CoHu61gWBD3VB1Pe67xWnjzuw-PSi7gWQ79uwS3Nd-nJH1gz'); return false">Lunesta Patient Instructions for Use</a>&nbsp
    <img src="/ct2/html/images/frame/exit.bmp" alt="This link exits the ClinicalTrials.gov site"/>
      </div>
    <br/>
  
    Publications:
  <div class="indent2">
            <div style="margin-top:2ex">
            Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. SLEEP 2010;33(2):225-234.
          </div>
              </div>
  <br/>
  
    Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
  <div class="indent2">
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9R0tagF8WR4B." title="Ancoli-Israel S, Krystal AD, McCall WV, Schaefer K, Wilson A, Claus R, Rubens R, Roth T. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010 Feb 1;33(2):225-34." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9R0tagF8WR4B.'); return false">Ancoli-Israel S, Krystal AD, McCall WV, Schaefer K, Wilson A, Claus R, Rubens R, Roth T. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010 Feb 1;33(2):225-34.</a>
          </div>
      </div>
  <br/>
  
  
  <table class="layout_table" style="margin-top:1ex" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Responsible Party:</td>
      <td style="padding-left:1em">Sepracor Inc. ( Executive Medical Director, Clinical Research )</td>
    </tr>
        <tr valign="top">
      <td nowrap>ClinicalTrials.gov Identifier:</td>
      <td style="padding-left:1em">
        <a title="Current version of study NCT00386334 on ClinicalTrials.gov" href="http://clinicaltrials.gov/ct2/show/NCT00386334">NCT00386334</a> &nbsp; &nbsp;
        <a href="/ct2/archive/NCT00386334"
          title="Historical versions of study NCT00386334 on ClinicalTrials.gov Archive Site"
          onclick="openNewWindow('/ct2/archive/NCT00386334'); return false;">History of Changes</a>
      </td>
    </tr>
            <tr valign="top">
      <td nowrap>Other Study ID Numbers:</td>
      <td style="padding-left:1em">190-904</td>
    </tr>
            <tr valign="top">
      <td nowrap>Study First Received:</td>
      <td style="padding-left:1em">October 9, 2006</td>
    </tr>
            <tr valign="top">
      <td nowrap>Results First Received:</td>
      <td style="padding-left:1em">February 13, 2009</td>
    </tr>
            <tr valign="top">
      <td nowrap>Last Updated:</td>
      <td style="padding-left:1em">November 2, 2010</td>
    </tr>
            <tr valign="top">
      <td nowrap>Health Authority:</td>
      <td style="padding-left:1em">United States: Food and Drug Administration</td>
    </tr>
      </table>

  
  <!-- keywords -->
    <br/>
  Keywords provided by Sunovion:
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    insomnia<br/>
                    chronic<br/>
                    primary<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  <!-- mesh terms -->
    <br/>
  Additional relevant MeSH terms:
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    Sleep Initiation and Maintenance Disorders<br/>
                    Sleep Disorders, Intrinsic<br/>
                    Dyssomnias<br/>
                  </td>
                <td width="50%" style="padding-left:1em">
                    Sleep Disorders<br/>
                    Nervous System Diseases<br/>
                    Mental Disorders<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  
  <br/>

    <span class="body3">ClinicalTrials.gov processed this record on March 02, 2011</span><br/>
  
  <br/>

</div>
</div>


<!-- Footer -->
<div class="skip"><a href="#MainContent">Back to top of Main Content</a></div>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<div align="center" class="footer">
  <br/>
  <a href="/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00386334%3Fterm%3Deszopiclone" onclick="openPopupWindow('/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00386334%3Fterm%3Deszopiclone',true); return false;">Contact Help Desk</a><br/>
  <a href="http://www.lhncbc.nlm.nih.gov">Lister Hill National Center for Biomedical Communications</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a>,<br/>
  <a href="http://www.nih.gov/">U.S. National Institutes of Health</a>,&nbsp;
  <a href="http://www.hhs.gov/">U.S. Department of Health &amp; Human Services</a>,<br/>
  <a href="http://www.usa.gov/">USA.gov</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a>,&nbsp;
  <a href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act</a><br/>

  <br/>
  <a href="http://www.nih.gov/"><img alt="U.S. National Institutes of Health" src="/ct2/html/images/frame/nih_logo.gif" border="0"/></a>
  <a href="http://www.nlm.nih.gov/"><img alt="U.S. National Library of Medicine" src="/ct2/html/images/frame/nlm_logo.gif" border="0"/></a>
  <a href="http://www.hhs.gov/"><img alt="U.S. Department of Health &amp; Human Services" src="/ct2/html/images/frame/hhs_logo.gif" border="0"/></a>

  <br/>
  <br/>
  <br/>
  <br/>
  <a href="/ct2/crawl" class="skip">Links to all studies - primarily for crawlers</a>
</div>

<!-- 2011:03:04 00:39:06.378  RRc0txt:SRc0fSH:I4Ya2XK -->
</body>
</html>
